Literature DB >> 2272320

The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule.

W Dippold1, A Steinborn, K H Meyer zum Büschenfelde.   

Abstract

The Thomsen-Friedenreich antigen (Gal-GalNAc) represents a tumor-associated molecule, which is assumed to be one of the few chemically well-defined antigens with a proven association with malignancy. In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, we immunized Balb/c mice with MCF-7 breast tumor cells together with synthetic Gal-GalNAc linked to a BSA carrier. One monoclonal antibody (82-A6) was established which recognizes the Thomsen-Friedenreich antigen according to the biochemical and serological analysis presented here. In contrast to the studies performed in the past, immunohistochemical results using this antibody 82-A6 did not exhibit a reactivity clearly restricted to tumors. Preliminary biochemical analysis revealed that the T-determinant is detectable in the high-molecular weight range (about 1000 kD), suggesting that the Gal-GalNAc epitope is found on mucinlike glycoproteins. Tumor restriction of Thomsen-Friedenreich antigen may therefore be determined either by the protein backbone or by the beta-glycosidic linkage of the carbohydrate structure to the protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2272320      PMCID: PMC1568008          DOI: 10.1289/ehp.9088255

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  10 in total

1.  Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens.

Authors:  T Feizi
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

2.  Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen.

Authors:  R Stein; S Chen; W Grossman; D M Goldenberg
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

3.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

Authors:  V G Johnson; J Schlom; A J Paterson; J Bennett; J L Magnani; D Colcher
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

Review 4.  Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives.

Authors:  S Hakomori
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

5.  A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen.

Authors:  A F Rahman; B M Longenecker
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

Review 6.  The Thomsen-Friedenreich (TF) receptor: an old history with new mystery.

Authors:  G Uhlenbruck
Journal:  Immunol Commun       Date:  1981

7.  A common epithelial cell surface antigen (EPM-1) on gastrointestinal tumors and in human sera.

Authors:  W G Dippold; H Bernhard; R Klingel; H P Dienes; G Kron; B Schneider; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

8.  T and Tn, general carcinoma autoantigens.

Authors:  G F Springer
Journal:  Science       Date:  1984-06-15       Impact factor: 47.728

9.  Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers.

Authors:  B M Longenecker; D J Willans; G D MacLean; S Selvaraj; M R Suresh; A A Noujaim
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

10.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

  10 in total
  3 in total

1.  Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.

Authors:  Jamie Heimburg; Jun Yan; Susan Morey; Olga V Glinskii; Virginia H Huxley; Linda Wild; Robert Klick; Rene Roy; Vladislav V Glinsky; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

2.  p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.

Authors:  Sabine Heublein; Sabina K Page; Doris Mayr; Nina Ditsch; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-02       Impact factor: 4.553

3.  Higher frequency of secretor phenotype in O blood group - its benefits in prevention and/or treatment of some diseases.

Authors:  Mohamad Salih Jaff
Journal:  Int J Nanomedicine       Date:  2010-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.